HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

International Stem Cell Corporation

This article was originally published in The Rose Sheet

Executive Summary

ISCO says its subsidiary Lifeline Skin Care is targeting late summer or fall of 2010 for a line of three cosmetic products based on the firm's stem cell technology. "Early human trials show that these cosmetic products moisturize skin and strongly indicate the ability to decrease the depth of wrinkles and provide factors that lead to anti-aging effects," according to April 8 release. The forthcoming line combines extracts from human parthenogenetic stem cells (hpSC) with a vitamin complex and relies on nanotechnology to deliver active ingredients to damaged skin, says Oceanside, California-based ISCO, which has partnered with fellow Californian Cosmetic Enterprises, Ltd. to formulate and package its offering. Company notes that use of hpSC "avoid[s] critical ethical issues by eliminating the need to use fertilized embryos and can be immune-matched to large segments of the population." "The Rose Sheet" spoke with ISCO Chairman Kenneth C. Aldrich in April of last year (1"The Rose Sheet" April 27, 2009)

You may also be interested in...



Stem-Cell-Based Anti-Aging Ingredient Under Development, Biotech Firm Says

A biotech firm that specializes in therapeutic products derived from human stem cells has a skin rejuvenation ingredient in the works, according to International Stem Cell Corporation's April 21 release

Lilly Taps Loxo Execs To Bring Back That Biotech Feeling

Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.

Tech Companies Grappling With A Brave New World Of Regulations While Developing Digital-Health Products

Software firms interested in the digital-health arena are engaging US FDA more and bolstering their regulatory credentials to navigate an unfamiliar regulatory landscape, industry experts tell Medtech Insight.

UsernamePublicRestriction

Register

RS016883

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel